Related references
Note: Only part of the references are listed.Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action
Kitsada Wudhikarn et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Cristina Perez et al.
BLOOD (2020)
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Lorenzo Galluzzi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Molecular mechanisms and cellular functions of cGAS-STING signalling
Karl-Peter Hopfner et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Cancer immunoediting and immune dysregulation in multiple myeloma
Kyohei Nakamura et al.
BLOOD (2020)
Multiple myeloma: the (r)evolution of current therapy and a glance into the future
Annamaria Gulla et al.
HAEMATOLOGICA (2020)
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
DNA Damage and Cancer Immunotherapy: A STING in the Tale
Timo Reislander et al.
MOLECULAR CELL (2020)
STING pathway agonism as a cancer therapeutic
Blake A. Flood et al.
IMMUNOLOGICAL REVIEWS (2019)
Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
Oliver Kepp et al.
ONCOIMMUNOLOGY (2019)
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
Alfonso Serrano-del Valle et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity (vol 25, pg 3074, 2018)
Kelsey E. Sivick et al.
CELL REPORTS (2019)
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma
A. Gulla et al.
LEUKEMIA (2018)
VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis
MacIntosh Cornwell et al.
BMC BIOINFORMATICS (2018)
Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma
Mehmet Kemal Samur et al.
LEUKEMIA (2018)
Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
Lien De Beck et al.
ONCOIMMUNOLOGY (2018)
The genetic landscape of 5T models for multiple myeloma
Ken Maes et al.
SCIENTIFIC REPORTS (2018)
cGAS Micro-Manages Genotoxic Stress
Mona Motwani et al.
IMMUNITY (2017)
Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance
Norma Bloy et al.
IMMUNOLOGICAL REVIEWS (2017)
cGAS surveillance of micronuclei links genome instability to innate immunity
Karen J. Mackenzie et al.
NATURE (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia
Xiufen Chen et al.
ONCOIMMUNOLOGY (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
The proteasome and proteasome inhibitors in multiple myeloma
Sara Gandolfi et al.
CANCER AND METASTASIS REVIEWS (2017)
Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era
Li Zhang et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo
Vidal Jarauta et al.
CANCER LETTERS (2016)
The host STING pathway at the interface of cancer and immunity
Leticia Corrales et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
IAP antagonists induce anti-tumor immunity in multiple myeloma
Marta Chesi et al.
NATURE MEDICINE (2016)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
Chromothripsis from DNA damage in micronuclei
Cheng-Zhong Zhang et al.
NATURE (2015)
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales et al.
CELL REPORTS (2015)
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
Fabrizio Accardi et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Type I interferons in anticancer immunity
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu et al.
NATURE MEDICINE (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data
Gabriela Bindea et al.
BIOINFORMATICS (2013)
INTERFEROME v2.0: an updated database of annotated interferon-regulated genes
Irina Rusinova et al.
NUCLEIC ACIDS RESEARCH (2013)
Bortezomib-induced BRCAness sensitizes multiple myeloma cells to PARP inhibitors
Paola Neri et al.
BLOOD (2011)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks
Gabriela Bindea et al.
BIOINFORMATICS (2009)
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Giada Bianchi et al.
BLOOD (2009)
The anticancer immune response: indispensable for therapeutic success?
Laurence Zitvogel et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications
Radek Spisek et al.
BLOOD (2007)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
George Mulligan et al.
BLOOD (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N Casares et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
